相关实验视频

Updated: Mar 17, 2026

Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus

Expanding Cytotoxic T Lymphocytes from Umbilical Cord Blood that Target Cytomegalovirus, Epstein-Barr Virus, and Adenovirus

Published on: May 7, 2012

在用Epcoritamab治疗的淋巴瘤患者中,与大肠杆菌,细胞巨乳病毒和SARS-CoV-2的三重感染

Osamu Imataki¹, Hina Takagi¹, Tomoya Ishida²

¹Hematology, Kagawa University, Miki, JPN.

|March 16, 2026

概括

新型淋巴瘤疗法epcoritamab针对B细胞,可能影响T细胞功能. 这一案例凸显了接受B细胞操纵疗法的患者需要保持警,尤其是在COVID-19等感染期间.

科学领域:

血液学血液学血液学
免疫学免疫学免疫学
在瘤学瘤学.

背景情况:

恶性淋巴瘤是一种常见的血液癌症,导致免疫性损害.
标准和新型疗法,包括化疗免疫疗法和针对B细胞的药物,可以进一步损害淋巴细胞功能.
作为双特异性T细胞吸引剂 (BiTE) 的epcoritamab将T细胞重定向攻击CD20+B细胞.

研究的目的:

报告一个用epcoritamab治疗的复发性恶性淋巴瘤病例.
描述患者在epcoritamab治疗期间与三重感染 (大肠杆菌,细胞巨化病毒,SARS-CoV-2) 的经验.
讨论B细胞操纵疗法对免疫功能和患者管理的影响.

主要方法:

一名患有复发性恶性淋巴瘤的患者在标准化疗免疫疗法 (R-CHOP,R-bendamustine) 后接受了epcoritamab.
在治疗期间,该患者患上了COVID-19肺炎,Campylobacter coli bacteremia和Cytomegalovirus antigenemia.
感染被用抗病毒和抗生素药物 (雷梅西维尔,美罗,甘西克洛维尔) 控制.

主要成果:

患者从感染中恢复过来,并得到了出院.
持续的SARS-CoV-2病毒流放被观察到超过六周.
埃普科里塔马布显示B细胞枯竭,但T细胞的长期影响尚不清楚.

结论:

包括epcoritamab在内的B细胞操纵疗法需要仔细监测感染并发症.
医疗保健提供者应注意接受这些新型治疗的患者潜在的免疫失调.
需要进一步的研究来了解epcoritamab和类似疗法对T细胞免疫的长期影响.

关键词:

坎比洛巴克特大肠杆菌 (campylobacter coli) 是一个大肠杆菌.在COVID-19中,有很多人.细胞巨型病毒 (cytomegalovirus) 是一种病毒.经过多年的研究,Epcoritamab.免疫功能受损的宿主恶性淋巴瘤是一种恶性淋巴瘤.这是SARS-CoV-2病毒.

更多相关视频

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.